ID   CPT-K5
AC   CVCL_2878
SY   CPT-K-5; CPTK5; RPMI 8402/CPTK5
DR   BioSample; SAMN03472497
DR   cancercelllines; CVCL_2878
DR   JCRB; JCRB1067
DR   Wikidata; Q54814409
RX   PubMed=1849260;
RX   PubMed=3039492;
RX   PubMed=14679002;
RX   PubMed=29496689;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Gene fusion; HGNC; HGNC:10879; STIL + HGNC; HGNC:11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=29496689).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11986; TOP1; Simple; p.Asp533Gly (c.1598A>G); ClinVar=VCV000016773; Zygosity=Unspecified (PubMed=1849260).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (from parent cell line).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): JCRB=JCRB1067; PubMed=29496689
ST   Amelogenin: X
ST   CSF1PO: 9,10,11,12
ST   D13S317: 10,12
ST   D16S539: 10,14
ST   D18S51: 14,17,18
ST   D19S433: 14,15
ST   D21S11: 28,30,33.2,34.2
ST   D2S1338: 23,24,26,27
ST   D3S1358: 14,15,16
ST   D5S818: 11,12,13
ST   D7S820: 9,12,14
ST   D8S1179: 13,14
ST   FGA: 21,22,24
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17,18,20,22
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1667 ! RPMI-8402
SX   Female
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 25
//
RX   PubMed=14679002;
RA   Li, Tsai-Kun
RA   Houghton, Peter J.
RA   Desai, Shyamal D.
RA   Daroui, Parima
RA   Liu, Angela A.
RA   Hars, Eszter S.
RA   Ruchelman, Alexander L.
RA   LaVoie, Edmond J.
RA   Liu, Leroy Fong
RT   "Characterization of ARC-111 as a novel topoisomerase I-targeting
RT   anticancer drug.";
RL   Cancer Res. 63:8400-8407(2003).
//
RX   PubMed=29496689; DOI=10.21873/cgp.20068; PMCID=PMC5892604;
RA   Kjeldsen, Eigil
RA   Nielsen, Christine J.F.
RA   Roy, Amit
RA   Tesauro, Cinzia
RA   Jakobsen, Ann-Katrine
RA   Stougaard, Magnus
RA   Knudsen, Birgitta Rudd
RT   "Characterization of camptothecin-induced genomic changes in the
RT   camptothecin-resistant T-ALL-derived cell line CPT-K5.";
RL   Cancer Genomics Proteomics 15:91-114(2018).
//
RX   PubMed=3039492; DOI=10.1073/pnas.84.16.5565; PMCID=PMC298903;
RA   Andoh, Toshiwo
RA   Ishii, Kazuyuki
RA   Suzuki, Yoshinobu
RA   Ikegami, Yoji
RA   Kusunoki, Yoichiro
RA   Takemoto, Yumi
RA   Okada, Kosuke
RT   "Characterization of a mammalian mutant with a camptothecin-resistant
RT   DNA topoisomerase I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5565-5569(1987).
//
RX   PubMed=1849260; DOI=10.1093/nar/19.1.69; PMCID=PMC333535;
RA   Tamura, Hiro-omi
RA   Kohchi, Chie
RA   Yamada, Ryutaro
RA   Ikeda, Tomotake
RA   Koiwai, Osamu
RA   Patterson, Eric
RA   Keene, Jack Donald
RA   Okada, Kosuke
RA   Kjeldsen, Eigil
RA   Nishikawa, Ken
RA   Andoh, Toshiwo
RT   "Molecular cloning of a cDNA of a camptothecin-resistant human DNA
RT   topoisomerase I and identification of mutation sites.";
RL   Nucleic Acids Res. 19:69-75(1991).
//